ArticleBMC nephrology2026
Treatment patterns, clinical outcomes, and economic burden among patients with immunoglobulin A nephropathy (IgAN) in China.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunoglobulin A nephropathy (IgAN) is a major cause of kidney failure. This study aimed to investigate the treatment patterns, clinical outcomes, and economic burden of IgAN in China.
methodsThis was a retrospective multicenter cohort study. Adult patients had biopsy-proven primary IgAN diagnosed between 01/01/2015, and 06/30/2023 in China. The index date was the date of the renal biopsy. Time-to-event analysis was performed for event-free from composite renal events (occurrence of end-stage kidney disease, a 40% decline in eGFR, doubling of serum creatinine, or a mortality event). Associations between proteinuria at renal biopsy and time-averaged proteinuria (TA-P) with composite renal events were estimated using Cox regression. Healthcare visit frequency per follow-up patient-year and costs per capita were calculated.
resultsThis study included 1,674 patients (median age: 37 years) with 60.27% hypertension. At renal biopsy, the median proteinuria of 1,211 patients was 1.42 g/day and two-thirds of them exhibited proteinuria ≥ 1 g/day. During follow-up (median: two years), renin-angiotensin-aldosterone system inhibitors (69.77%) and corticosteroids (66.98%) were the most prescribed medications for IgAN; and 9.20% of patients experienced composite renal events. The probability of remaining composite renal event-free was 65.1% in the 8th year. Higher proteinuria levels were associated with an increased risk of composite renal events (hazard ratios with 95% confidence intervals: 1.18 [0.49, 2.80] for 0.5–<1 g/day, 1.77 [0.80, 3.94] for 1–<2 g/day, 2.98 [1.25, 7.07] for 2–<3 g/day and 7.73 [3.67, 16.26] for ≥ 3 g/day vs. < 0.5 g/day TA-P). On average, per follow-up year, each patient had seven outpatient nephrology visits, one hospitalization, and 14 days of hospital stay. In 2015–2023, the per capita hospital care cost was 1,847 USD; and costs increased with higher proteinuria levels or advancing chronic kidney disease stages.
conclusionsResults showed that despite of available therapies, patient outcomes remained poor, emphasizing the need for better therapeutic strategies to address the clinical and economic challenges posed by IgAN in China.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.